|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Journal of Lipid Research, Vol. 45, 2000-2007, November 2004
Copyright © 2004 by American Society for Biochemistry and Molecular Biology
Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, TN 37232-0146
1 To whom correspondence should be addressed. e-mail: aouatef.bellamine{at}vanderbilt.edu
14
-Demethylase (CYP51) is a key enzyme in all sterol biosynthetic pathways (animals, fungi, plants, protists, and some bacteria), catalyzing the removal of the C-14 methyl group following cyclization of squalene. Based on mutations found in CYP51 genes from Candida albicans azole-resistant isolates obtained after fluconazole treatment of fungal infections, and using site-directed mutagenesis, we have found that fluconazole binding and substrate metabolism vary among three different CYP51 isoforms: human, fungal, and mycobacterial. In C. albicans, the Y132H mutant from isolates shows no effect on fluconazole binding, whereas the F145L mutant results in a 5-fold increase in its IC50 for fluconazole, suggesting that F145 (conserved only in fungal 14
-demethylases) interacts with this azole. In C. albicans, F145L accounts, in part, for the difference in fluconazole sensitivity reported between mammals and fungi, providing a basis for treatment of fungal infections. The C. albicans Y132H and human Y145H CYP51 mutants show essentially no effect on substrate metabolism, but the Mycobacterium tuberculosis F89H CYP51 mutant loses both its substrate binding and metabolism.
Because these three residues align in the three isoforms, the results indicate that their active sites contain important structural differences, and further emphasize that fluconazole and substrate binding are uncoupled properties.
Abbreviations: 14DM/CYP51, cytochrome P450 sterol 14
-demethylase; 24M-DHL, 24-methylene dihydrolanosterol; ATCC, American Type Culture Collection; CA, Candida albicans; DHL, 24,25-dihydrolanosterol; DLPC, dilauryl-L-
-phosphatidylcholine; H, human; MT, Mycobacterium tuberculosis
Supplementary key words Candida albicans, human inhibitor binding Mycobacterium tuberculosis substrate metabolism
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
J. E. Parker, M. Merkamm, N. J. Manning, D. Pompon, S. L. Kelly, and D. E. Kelly Differential Azole Antifungal Efficacies Contrasted Using a Saccharomyces cerevisiae Strain Humanized for Sterol 14{alpha}-Demethylase at the Homologous Locus Antimicrob. Agents Chemother., October 1, 2008; 52(10): 3597 - 3603. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. N. Eddine, J. P. von Kries, M. V. Podust, T. Warrier, S. H. E. Kaufmann, and L. M. Podust X-ray Structure of 4,4'-Dihydroxybenzophenone Mimicking Sterol Substrate in the Active Site of Sterol 14{alpha}-Demethylase (CYP51) J. Biol. Chem., May 30, 2008; 283(22): 15152 - 15159. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Kudo, M. Ohi, Y. Aoyama, Y. Nitahara, S.-K. Chung, and Y. Yoshida Effects of Y132H and F145L Substitutions on the Activity, Azole Resistance and Spectral Properties of Candida albicans Sterol 14-Demethylase P450 (CYP51): A Live Example Showing the Selection of Altered P450 through Interaction with Environmental Compounds J. Biochem., May 1, 2005; 137(5): 625 - 632. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Matsuura, S. Yoshioka, T. Tosha, H. Hori, K. Ishimori, T. Kitagawa, I. Morishima, N. Kagawa, and M. R. Waterman Structural Diversities of Active Site in Clinical Azole-bound Forms between Sterol 14{alpha}-Demethylases (CYP51s) from Human and Mycobacterium tuberculosis J. Biol. Chem., March 11, 2005; 280(10): 9088 - 9096. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Journal of Biological Chemistry |
| Molecular and Cellular Proteomics | ASBMB Today |